AstraZeneca’s MCL-1 cancer drug put on hold after flagging a safety issue — 2 years after Amgen axed rival drug

Two years after the FDA hit Amgen with a clinical hold on its MCL-1 inhibitor AMG 397 following signs of cardiac toxicity, AstraZeneca is now flagging safety issues for a rival therapy of the same class. The pharma giant noted on clinicaltrials.gov that its Phase I/II study for the MCL-1…

...

Click to view original post